



Jadenu® Sprinkle (deferasirox) – First-time generic

- On August 5, 2020, Ascend launched Alkem's [AB-rated](#) generic version of Novartis' [Jadenu Sprinkle \(deferasirox\)](#) granules.
- Jadenu is approved for the treatment of chronic iron overload due to blood transfusions (transfusional iron overload) and treatment of chronic iron overload in non-transfusion-dependent thalassemia syndromes.
- Deferasirox is also available generically as a [tablet](#) and a [dispersible tablet](#) for suspension.
 - Both formulations carry the same indications as Jadenu Sprinkle.
- Jadenu Sprinkle carries a boxed warning for renal failure, hepatic failure, and gastrointestinal hemorrhage.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.